Robust Use of Janssen's Tremfya and Positive Early Launch Metrics for AbbVie's Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights

[In The News]

EXTON, Pa., July 25, 2019 /PRNewswire/ -- Spherix began tracking the US psoriasis market through its RealTime Dynamix™: Psoriasis (US) service in early 2016, just one year following the launch of Novartis' Cosentyx. The 2015 FDA approval of the first IL-17 inhibitor to enter the field...

View the full article